F-star Therapeutics, Inc. (FSTX)
Price:
7.12 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
NEWS
F-star's Delayed Acquisition Presents A Risky Opportunity
seekingalpha.com
2023-01-28 16:00:00FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
seekingalpha.com
2022-07-29 10:15:47F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
New Strong Buy Stocks for July 15th
zacks.com
2022-07-15 08:19:07GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
zacks.com
2022-06-24 11:40:20Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
F-star Therapeutics Shares Are Rallying Today - Read Why
benzinga.com
2022-06-23 09:27:03invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million.
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-10 10:32:16Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com
2022-05-03 16:33:41Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-14 12:45:24F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
globenewswire.com
2022-03-10 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
globenewswire.com
2022-03-02 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
seekingalpha.com
2022-01-27 07:29:54The company's unique selling proposition is its novel, tetravalent bispecific antibody platform which has earned validation through partnership deals with big pharma like Merck.
F-star Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
2022-01-07 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it will participate in the H.C. Wainwright Bioconnect Conference and the B. Riley Securities' 2022 Oncology Conference taking place virtually on January 10-13, and January 27-28, 2022, respectively.
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
globenewswire.com
2021-12-07 09:05:00First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications
F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-11-15 07:43:04F-star Therapeutics (FSTX) has been struggling lately, but the selling pressure may be coming to an end soon.
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-14 08:37:05F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
globenewswire.com
2021-11-12 08:00:00Dr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific
No data to display
F-star's Delayed Acquisition Presents A Risky Opportunity
seekingalpha.com
2023-01-28 16:00:00FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
seekingalpha.com
2022-07-29 10:15:47F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
New Strong Buy Stocks for July 15th
zacks.com
2022-07-15 08:19:07GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
zacks.com
2022-06-24 11:40:20Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
F-star Therapeutics Shares Are Rallying Today - Read Why
benzinga.com
2022-06-23 09:27:03invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million.
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-10 10:32:16Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com
2022-05-03 16:33:41Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-14 12:45:24F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
globenewswire.com
2022-03-10 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
globenewswire.com
2022-03-02 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
seekingalpha.com
2022-01-27 07:29:54The company's unique selling proposition is its novel, tetravalent bispecific antibody platform which has earned validation through partnership deals with big pharma like Merck.
F-star Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
2022-01-07 08:00:00CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it will participate in the H.C. Wainwright Bioconnect Conference and the B. Riley Securities' 2022 Oncology Conference taking place virtually on January 10-13, and January 27-28, 2022, respectively.
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
globenewswire.com
2021-12-07 09:05:00First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications
F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-11-15 07:43:04F-star Therapeutics (FSTX) has been struggling lately, but the selling pressure may be coming to an end soon.
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-14 08:37:05F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
globenewswire.com
2021-11-12 08:00:00Dr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific